WuXi AppTec's subsidiary for new drug development has reduced its capital to approximately 2.58 billion

Zhitong
2025.10.28 03:37

According to the Tianyancha App, recently, Shanghai WuXi AppTec New Drug Development Co., Ltd. underwent a business change, with its registered capital reduced from approximately 12.46 billion RMB to about 2.58 billion RMB, a decrease of about 79%. The company was established in April 2002, with Zhang Chaohui as the legal representative. Its business scope includes health consulting, pharmaceutical consulting, and self-owned real estate development and operation, all wholly owned by WuXi AppTec

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.